Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer

PHASE3RecruitingINTERVENTIONAL
Enrollment

378

Participants

Timeline

Start Date

September 7, 2021

Primary Completion Date

February 28, 2026

Study Completion Date

July 31, 2029

Conditions
Pancreatic CancerPancreatic Ductal AdenocarcinomaResectable Pancreatic Adenocarcinoma
Interventions
DRUG

Leucovorin Calcium

IV

DRUG

Fluorouracil

IV

DRUG

Irinotecan Hydrochloride

IV

DRUG

Oxaliplatin

IV

PROCEDURE

Resection

Open or minimally-invasive pancreatectomy.

Trial Locations (22)

Unknown

RECRUITING

Jeroen Bosch Hospital, 's-Hertogenbosch

RECRUITING

Meander Medical Center, Amersfoort

RECRUITING

Amsterdam UMC, Amsterdam

RECRUITING

OLVG, Amsterdam

RECRUITING

Amphia Hospital, Breda

RECRUITING

Deventer Hospital, Deventer

RECRUITING

Catharina Hospital, Eindhoven

RECRUITING

Medisch Spectrum Twente, Enschede

RECRUITING

University Medical Center Groningen, Groningen

RECRUITING

Tjongerschans Hospital, Heerenveen

RECRUITING

Medical Center Leeuwarden, Leeuwarden

RECRUITING

Leiden University Medical Center, Leiden

RECRUITING

Maastricht UMC+, Maastricht

RECRUITING

Radboud University Medical Center, Nijmegen

RECRUITING

Erasmus MC University Medical Center, Rotterdam

RECRUITING

Maasstad Ziekenhuis, Rotterdam

RECRUITING

Regional Academic Center Utrecht, Antonius Hospital, Utrecht

RECRUITING

Isala Hospital, Zwolle

NOT_YET_RECRUITING

Oslo University Hospital, Oslo

RECRUITING

Sahlgrenska University Hospital, Gothenburg

RECRUITING

Skåne University Hospital, Lund

RECRUITING

Karolinska University Hospital, Stockholm

Sponsors
All Listed Sponsors
collaborator

Dutch Pancreatic Cancer Group

UNKNOWN

collaborator

Dutch Cancer Society

OTHER

lead

Erasmus Medical Center

OTHER